Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from FDA

US court restricts access to mifepristone abortion pill, sending case to Supreme Court

A US federal appeals court on Wednesday imposed restrictions on a widely used abortion pill, but the ruling will remain on hold as the Supreme Court decides whether to hear the case.

France 24

An appeals court backs some abortion drug limits, pending the Supreme Court’s approval

A federal appeals panel upholds a lower-court ruling banning mail-order delivery of mifepristone and allows its use only through the seventh week of pregnancy. The ruling won’t take effect until the high court weighs in.

Chicago Sun-Times

US appeals court upholds limits on access to abortion pill mifepristone

The latest ruling over mifepristone’s FDA approval is likely to send the pill’s fate to the US Supreme Court.

Al Jazeera

From analysis to the latest developments in health,
read the most diverse news in one place.

Decision sets up likely Supreme Court showdown on abortion pill - Roll Call

The 5th Circuit Court of Appeals ruling left in place the FDA’s initial approval of the drug, but struck changes made to ease access to it.

Roll Call

US appeals court upholds restrictions on abortion pill access

Ruling prevents mifepristone being prescribed by non-doctors or shipped by mail but does not order drug off market

The Guardian - US

Abortion drug case likely headed to Supreme Court after Republican-appointed judges agree to restrict access

A widely used abortion drug will remain available under existing regulations while a legal battle plays out

The Independent UK

Some abortion drug restrictions are upheld by an appeals court in a case bound for the Supreme Court

New restrictions on access to a drug used in the most common form of abortion would be imposed under a federal appeals court ruling

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

What are partially hydrogenated oils?

Also called PHOs, here is why the FDA is attempting to ban them

Salon

The Psychedelic Renaissance Is Here

Inside the gathering of the scientists, psychonauts, capitalists, and comedians committed to mainstreaming psychedelics without repeating the errors of the 1960s.

Reason

FDA approves new ‘spiral’ tampon shape

For the first time in decades, the products could get a significant update, which makers say better absorbs fluid

The Guardian - US

Nestlé recalling batches of its famous cookie dough wood fragment fears

No reports of illnesses or deaths have been recorded by the FDA, but Nestle said it is recalling select batches “out of an abundance of caution.”

Fortune

GOP senator amplifies conspiracy theory that Covid was ‘pre-planned’ by ‘elite’ in anti-vaccine rant on Fox

Ron Johnson and Maria Bartiromo falsely claimed the FDA ‘approves’ ivermectin to treat the disease

The Independent UK

Are your supplements harming you?

A $50 billion industry has grown around underregulated substances you probably don't need and may even hurt you

Salon

The True Story Behind 'Painkiller,' From Richard Sackler to Purdue Pharma

The scripted miniseries covers all angles of the opioid epidemic

Marie Claire

Get all your
news in one place.

100's of premium titles.
One news app.

Reason

AOC Slams the FDA's Harmful Overregulation of Sunscreen

On this one issue, the democratic socialist sounds a lot like a libertarian.

LiveScience

Ice cream cups sold in 20 states linked to Listeria outbreak, CDC warns

"Soft Serve On The Go" ice cream cups have been recalled due to potential bacterial contamination.

Reason

Premium Cigars Escape FDA Regulation for Now

The FDA failed to consider whether premium cigars warranted a different regulatory approach than cigarettes.

Fortune

A pharma company helping Elon Musk shed weight is now worth more than the entire economy of Denmark

The weight-loss and diabetes injectables have seen a surge in demand primarily in the U.S., buoying Novo Nordisk’s profits in the first half of 2023.

Get all your
news in one place.

100's of premium titles.
One news app.

WEKU

Coronavirus FAQ: Is it wiser to get a booster now or wait for the new fall booster?

Maybe it's not a full-blown summer surge but COVID numbers are ticking up. For those with concerns due to personal risk factors or the start of the school year, the booster question is top of mind.

The Independent UK

Insurers won't cover new Alzheimer's treatment for some customers

Some private insurers are balking at paying for the first drug fully approved to slow mental decline in Alzheimer’s patients

Reason

Suicide Down 8.4 Percent Among Teens and Young Adults

Plus: How would Jesus vote?, appeals court strikes gun ban for marijuana users, and more...

LiveScience

Can Ozempic and Wegovy cause 'stomach paralysis' and 'cyclic vomiting'?

"Stomach paralysis" linked to drugs like Ozempic has raised alarm. What do doctors make of the reports?

Zenger

Elon Musk-Backed Brain Chip Company Neuralink Gets $280 Million In Funding

Neuralink receives approval from the FDA for human experiment trials as experimentation looms.

WEKU

What we know — and don't know — about the FDA-approved postpartum depression pill

Postpartum depression affects as many as 1 in 7 women in the U.S., though there are just two treatments approved for it. Experts say the newest could be a game-changer — depending on its price tag.

StockNews.com

3 Pharma Stocks Investors Are Chasing for Value

With the advent of advanced medications and the increasing need for personalized treatments, the pharmaceutical industry looks well-poised for long-term growth. Therefore, it could be worth looking into three fundamentally sound pharma stocks, Pfizer (PFE), Sanofi (SNY), and GSK plc (GSK), that are offering significant value. Read more….

1 … 117 118 119 120

People

Alexandria OcasioCortez

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.